A previous report by our group (Mimica et al., 2016) demonstrated that the Neutrophil to Lymphocyte Ratio (NLR), a measure of systemic inflammation routinely used in the clinic, was associated to aggressive BC subtypes, including epidermal growth factor receptor type 2 (HER2) overexpressing or triple negative tumors; predicting survival in the first. The gene discussed is ERBB2; the disease is breast cancer.